Zika transmission has been reported in more than 90 countries as the spread of the Aedes aegypti mosquito that carries the ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Due to air pollution in Colombo and its suburbs, there is an increase in health issues such as respiratory difficulties, coughing, childhood asthma and viral respiratory infections, Lady Ridgeway ...

“The number of ZVD cases reported in 2024 in Maharashtra state is the highest since 2021 compared with respectively one, ...

Zika virus is currently present in over 90 countries and spreading at a rapid pace, thanks to Aedes aegypti mosquitoes, which ...

A study from the Liverpool School of Tropical Medicine reveals that Zika virus alters human skin chemistry, increasing volatile organic compounds that attract mosquitoes. This boosts virus ...

Future Virology. 2008;3(2):179-192. Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can be confused with diseases such as dengue or yellow fever, based on the similarity ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.

Recent outbreak of Guillain–Barré syndrome in Pune causing panic, symptoms, diagnosis, treatment, and prevention explained in detail.